Ho Ambrose Chung-Wai, Ho Wai-Kuen, Lam Paul Kin-Yip, Yuen Anthony Po-Wing, Wei William Ignace
Division of Otorhinolaryngology Head and Neck Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
Head Neck. 2008 Mar;30(3):336-40. doi: 10.1002/hed.20693.
Hypothyroidism is 1 of the complications that follow treatment of various head and neck cancers. In the literature, reviews using different primary sites and differences in treatment modalities make comparison of post-treatment hypothyroidism not possible. The objective of this study was to evaluate the incidence of hypothyroidism in a homogenous group of patients who were treated with total laryngectomy and irradiation for laryngeal carcinoma and to assess the importance of different variables in the occurrence of hypothyroidism.
A retrospective review of 147 total laryngectomy patients between 1993 and 2003 was carried out. Serum thyroxine level and free T4 levels were assessed in all patients. Hypothyroidism was classified as subclinical (increased thyroid-stimulating hormone and normal free T4 levels) and clinical (increased thyroid-stimulating hormone and decreased free T4 levels).
The results showed that the overall incidence of hypothyroidism was 49% (44% subclinical and 5% clinical). Hemithyroidectomy and advanced tumor staging were risk factors for the development of hypothyroidism in these patients (p < .05) with a relative risk of 2.1 (CI 95%, 1.4-3.1) and 1.3 (CI 95%, 1.1-1.6), respectively. During follow-up, 19.9% of patients developed hypothyroidism at 3 years, 38.6% at 6 years; at 10 year follow-up, 93.3% of them had hypothyroidism.
In conclusion, hypothyroidism is a frequent complication in patients treated with radiotherapy and total laryngectomy for laryngeal cancer, especially when treatment includes hemithyroidectomy. These patients should have their thyroid function evaluated periodically even 10 years after treatment.
甲状腺功能减退是各种头颈癌治疗后的并发症之一。在文献中,由于使用的原发部位不同以及治疗方式存在差异,使得对治疗后甲状腺功能减退进行比较变得不可能。本研究的目的是评估一组接受全喉切除术及放疗治疗喉癌的同质患者中甲状腺功能减退的发生率,并评估不同变量在甲状腺功能减退发生中的重要性。
对1993年至2003年间的147例全喉切除术患者进行回顾性研究。对所有患者评估血清甲状腺素水平和游离T4水平。甲状腺功能减退分为亚临床型(促甲状腺激素升高而游离T4水平正常)和临床型(促甲状腺激素升高且游离T4水平降低)。
结果显示甲状腺功能减退的总体发生率为49%(亚临床型44%,临床型5%)。甲状腺半切术和肿瘤晚期分期是这些患者发生甲状腺功能减退的危险因素(p < 0.05),相对风险分别为2.1(95%可信区间,1.4 - 3.1)和1.3(95%可信区间,1.1 - 1.6)。在随访期间,19.9%的患者在3年时出现甲状腺功能减退,6年时为38.6%;在10年随访时,93.3%的患者患有甲状腺功能减退。
总之,甲状腺功能减退是接受放疗和全喉切除术治疗喉癌患者的常见并发症,尤其是当治疗包括甲状腺半切术时。即使在治疗10年后,这些患者也应定期评估甲状腺功能。